Press Releases

Date Title and Summary View
Jun 03, 2013
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013—MacroGenics, Inc.
Additional Formats
May 21, 2013
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer ROCKVILLE, Maryland - May 21, 2013/PRNewswire/ - MacroGenics, Inc.
Additional Formats
Jan 07, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products

<ul>
<li>Based on MacroGenics&#8217; proprietary DART technology for generating bi-specific antibodies</li>
<li>Gilead receives rights to four pre-clinical programs</li>
<li>MacroGenics retains development and commercial rights to one of the programs in major markets outside North America and the European Union</li></ul>

Additional Formats
Sep 20, 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

<ul>
<li>Includes three novel pre-clinical programs for the treatment of solid and liquid tumors</li>
<li>Based on MacroGenics' proprietary DART technology for generating bi-specific antibodies that redirect the body's own immune system to kill cancer cells</li>
<li>MacroGenics retains full rights to each program in North America, Japan, Korea and India</li>
<li>Servier has the option to obtain exclusive license to develop and commercialize each program in the rest of the world</li></ul>

Additional Formats
Sep 05, 2012
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases Los Angeles, CA and Rockville, MD – September 5, 2012. ImaginAb, Inc.
Additional Formats
Dec 20, 2011
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim
ROCKVILLE , Maryland , December 20, 2011- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.   The milestone payment was triggered as part of an agreement
Additional Formats
Dec 01, 2011
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug

<ul>
<li>MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide variety of solid tumors</li>
<li>MacroGenics retains full program rights in North America, Japan, Korea and India</li>
<li>Servier has an option to obtain an exclusive license to develop and commercialize MGA271 in the rest of the world</li></ul>

Additional Formats
Jun 28, 2011
The Lancet Publishes Data from Protégé, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
ROCKVILLE , MD. , June 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protégé, a Phase 3 clinical study of teplizumab
Additional Formats
Jun 23, 2011
MacroGenics Announces Presentation of Protégé Phase 3 Clinical Data at ADA in San Diego on June 28
ROCKVILLE, MD., June 23 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protégé, the Company’s Phase 3 clinical study of teplizumab in type
Additional Formats
Apr 28, 2011
Data Published in Blood Demonstrate Potent Activity of MacroGenics' Proprietary DART™ Technology
ROCKVILLE , MD. , April 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent
Additional Formats
Jan 06, 2011
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-Expressing Solid Tumors
ROCKVILLE , MD. , January 6 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical
Additional Formats
Oct 26, 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics INGELHEIM, Germany and ROCKVILLE, MD, USA, October 26, 2010 -- Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global
Additional Formats
Oct 26, 2010
MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
ROCKVILLE, MD, October 26, 2010 -- MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting
Additional Formats
Oct 20, 2010
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint ROCKVILLE, Md., INDIANAPOLIS, Ind. – Oct. 20, 2010 – MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protégé Data Monitoring Committee (DMC), composed of
Additional Formats
Jul 15, 2010
MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding further Advances DART Platform and Infectious Disease Portfolio
ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants
Additional Formats
Jan 07, 2010
MacroGenics Appoints New Senior Vice President of Clinical Development
MacroGenics Appoints New Senior Vice President of Clinical Development ROCKVILLE , Md. , January 7 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment
Additional Formats
Jul 13, 2009
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
ROCKVILLE , Md. , July 13, 2009 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the trea tment of individuals with suspected central nervous system infection due to West Nile
Additional Formats
Jun 23, 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Paulo F. Costa Joins MacroGenics Board of Directors ROCKVILLE, MD., June 23, 2009 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis
Additional Formats
Jun 16, 2009
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTÉGÉ, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

Phase 3 PROT&#201;G&#201; ENCORE Clinical Trial Initiated

Additional Formats
Mar 26, 2009
MacroGenics Appoints New Vice President of Business Development
MacroGenics Appoints New Vice President of Business Development ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric
Additional Formats
Sep 25, 2008
MacroGenics Raises $25M in Series D-2 Financing

Proceeds to be Used for Advancement of Cancer Stem Cells and Other Development Programs

Additional Formats
Jul 17, 2008
MacroGenics Acquires Raven Biotechnologies

Raven's Discovery Platform in Cancer Stem Cell Biology<br>Enhances MacroGenics' Oncology Capabilities and Complements Proprietary Antibody Technology Platforms

Additional Formats
May 06, 2008
Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer
Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer Rockville, Maryland.   May 6, 2008.  MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the
Additional Formats
Oct 18, 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement

Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments

Additional Formats
Sep 26, 2007
Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman
Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development
Additional Formats